ALDERIA INTELLIGENCE
← All signals
PubMed17 Apr 2026·Circulation. Population health and outcomes● 4/10i

Leveraging Neighborhood-Level Interventions to Improve Cardiovascular Health: A Scoping Review.

Choudhury SH, Holmes DM, Ekwunife OI, Campbell JA, Walker RJ et al.

Neighborhood-level interventions improved cardiovascular health behaviors in 55% of studies, with dietary outcomes showing greatest benefit at 73% and physical activity at 63%. Scoping review of 20 studies including 15 RCTs and 5 quasi-experimental studies targeting built environments, food access, and housing mobility. This provides the first systematic evidence that environmental modifications combined with community support can address social determinants of cardiovascular disease at population scale. However, interventions showed limited impact on clinical cardiometabolic risk factors, suggesting behavioral changes may not translate to measurable health outcomes.

Strategic signal

This evidence strengthens the case for pharmaceutical companies to integrate social determinants of health into their cardiovascular and metabolic disease strategies. CMS and European HTA bodies increasingly evaluate real-world effectiveness and health equity in coverage decisions, making population health interventions a competitive differentiator. Companies like Novo Nordisk and Eli Lilly could leverage these findings to support value-based contracts that combine GLP-1 therapies with community interventions, potentially improving adherence and outcomes while addressing payer concerns about access disparities.

CardiovascularReal-world evidence

Original Abstract

Cardiovascular disease remains the leading cause of death globally. Neighborhood characteristics such as food environments, green space access, and housing conditions shape cardiovascular health by influencing environmental exposures, resource access, and chronic stress, with disproportionate impacts on socially vulnerable populations. This scoping review aims to identify and evaluate neighborhood-level interventions designed to promote cardiovascular health and determine which strategies are most effective in improving health outcomes. A comprehensive and reproducible search was conducted across PubMed, ScienceDirect, Web of Science, and OVID Medline for studies published between 2015 and 2025. Keywords related to neighborhood-level interventions and cardiovascular health were used to identify relevant articles. Neighborhood-level interventions were defined as strategies that modify the physical, social, or economic environment of geographically defined areas. Outcomes included cardiovascular health behaviors, cardiometabolic risk factors, and clinical cardiovascular outcomes. Twenty studies were included, including 15 randomized controlled trials and 5 quasi-experimental studies. Interventions targeted built environments, food retail environments, housing mobility, or employed multicomponent approaches that coupled environmental intervention with individual or community-level support. Overall, 55% of studies demonstrated beneficial cardiovascular outcomes, 20% showed mixed effects, and 25% showed null effects. Dietary behavior outcomes showed the greatest benefit (73%), followed by physical activity (63%), while cardiometabolic risk factors showed limited improvement. Interventions were particularly effective when they integrated environmental changes with support across multiple levels, including education, peer support, and community resources. Multicomponent interventions coupling neighborhood environmental modifications with either individual or community-level support show promise for improving cardiovascular health behaviors, particularly physical activity and diet in disadvantaged populations. Future work should prioritize long-term studies on interventions that integrate these elements to understand sustainability and measure cost-effectiveness to facilitate implementation of strategies and policy changes that sustain long-term health improvements.

Related signals

ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

Phase 3 cardiovascular outcomes trial testing orforglipron versus placebo in people with established atherosclerotic cardiovascular disease and/or chronic kidney disease. Event-driven study enrolling 7,140 participants with expected completion in August 2031, approximately 5 years duration. This positions Eli Lilly to compete directly with Novo Nordisk's cardiovascular claims for semaglutide by establishing orforglipron as the first small-molecule oral GLP-1 with proven cardiovascular benefits. The trial targets a high-risk population already established for GLP-1 cardiovascular benefit validation.

GLP-1CardiovascularEli Lilly
ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Phase 3 open-label trial compared once-daily oral orforglipron versus insulin glargine in people with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study enrolled 2,749 participants with primary endpoint of time to first major adverse cardiovascular event, completed in March 2026. Eli Lilly is positioning orforglipron as a cardiovascular outcomes option in high-risk populations, directly competing with established insulin therapy in this indication. This represents the first cardiovascular outcomes trial for orforglipron following its April 2026 FDA approval for type 2 diabetes.

GLP-1Type 2 diabetesWeight lossCardiovascularEli Lilly
PubMed28 Mar 2026·JAMA cardiology● 8/10iHigh impact

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.

Tirzepatide reduced a 6-component cardiorenal composite endpoint by 16% versus dulaglutide (23.7% vs 27.4%, HR 0.84) in people with type 2 diabetes and cardiovascular disease. Post hoc analysis of SURPASS-CVOT double-blind RCT, 13,165 patients, median 46.9 months follow-up. This provides the first head-to-head cardiorenal comparison between tirzepatide and a GLP-1 agonist in high-risk cardiovascular patients, extending beyond the primary non-inferiority finding. Gastrointestinal adverse events were higher with tirzepatide (42.5% vs 35.9%).

GLP-1CardiovascularKidneyType 2 diabetesDrug comparisonsEli LillyNovo Nordisk
ClinicalTrials12 Mar 2026·Phase 3● 8/10iHigh impact

The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

Phase 3 cardiovascular outcomes trial evaluating CagriSema (cagrilintide + semaglutide 2.4 mg/2.4 mg) versus placebo in people with established cardiovascular disease. 7,101 participants enrolled with up to 4.5 years follow-up, measuring time to first 3-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke). Novo Nordisk is testing whether their dual amylin/GLP-1 combination can deliver cardiovascular benefits beyond current GLP-1 monotherapy in high-risk populations. This represents the first major cardiovascular outcomes trial for a dual incretin/amylin combination therapy.

GLP-1CardiovascularWeight lossNovo Nordisk

Weekly briefing

Key signals, decoded for pharma executives and investors. Free, every week.